Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

Completed · Not applicable

Conditions studied: Adenocarcinoma of the Prostate

In brief

This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.

Key facts

Study ID

NCT02523924

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

50

Starts

2015-06-02

Expected to finish

2019-03-04

Last updated by the study team

2020-01-31

Who can join

Age: 18 and older, up to 100. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• History of adenocarcinoma of the prostate treated with radical prostatectomy
• Serum PSA level ≥0.2 ng/mL at least 45 days prior to study enrollment
• Completed staging evaluation with bone scan as well as CT or MRI of the abdomen and pelvis at least 45 days prior to study enrollment

You may not qualify if…

• Intention to enroll in a blinded therapeutic clinical trial
• History of other malignancy diagnosed within the last three years (the exception of squamous cell or basal cell carcinoma of the skin)

Where it is running

• SKCCC — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.